Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database

Abstract

Background:

People with gender dysphoria are treated with hormone therapy for gender reassignment. The indication of this therapy was initially for the opposite sex, and information on potential adverse drug reaction (ADR) is lacking.

Objective:

To describe ADR associated with gender transition medication in transgender individuals reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods:

Data from the FAERS database up to June 2023 were examined, focusing on reports of gender transition medication use in the context of gender dysphoria. The ADRs were categorized using the Medical Dictionary for Regulatory Activities at both Preferred Term and System Organ Class (SOC) levels. Descriptive statistics summarized report counts, medication types, indications, and ADR severity.

Results:

For individuals assigned female at birth undergoing gender transition to male (transgender men), 82 reports (230 ADRs) were analyzed, with an average age of 29.5 years. Transgender hormonal therapy was cited in 72% of reports, predominantly from the United States (67.1%). A striking 88% were categorized as serious ADRs, primarily SOC injury, poisoning, and procedural complications (26.5%), followed by psychiatric disorders (14.8%) and nervous system disorders (12.2%). Among those assigned sex male at birth transitioning to female (transgender women) (81 reports, 237 ADRs), mean age was 33.3 years, with 58% indicating use for gender dysphoria. A significant proportion (53.6%) were serious ADRs, primarily SOC: injury, poisoning, and procedural complications (26.6%).

Conclusions and Relevance:

The FAERS data reveal significant ADRs in transgender individuals using hormone therapy, sometimes unintended for their recipient gender. Population-level studies are crucial to enhance transgender health care. Spontaneous surveillance databases like FAERS illuminate off-label ADRs, urging health care providers to approach hormone therapies with informed caution.

Keywords

transgender persons transgender health drug-related side effects and adverse reactions adverse drug reaction reporting systems drug toxicity

Get full access to this article

View all access options for this article.

References

Guss

Shumer

Katz-Wise

SL.

Transgender and gender nonconforming adolescent care: psychosocial and medical considerations. Curr Opin Pediatr. 2015;27(4):421-426. doi:10.1097/MOP.0000000000000240.

Distiller

. Thought bodies: gender, sex, sexualities. In: Distiller

, ed. Complicities: A Theory for Subjectivity in the Psychological Humanities. Palgrave Studies in the Theory and History of Psychology. Cham: Springer; 2022:107-161. doi:10.1007/978-3-030-79675-4_4.

Garg

Elshimy

Marwaha

Gender dysphoria. In: StatPearls. StatPearls; 2023. Accessed June 14,2023. http://www.ncbi.nlm.nih.gov/books/NBK532313/.

American Psychiatric Association. A guide for working with transgender and gender nonconforming patients: gender dysphoria diagnosis. Accessed May 2023. https://www.psychiatry.org/psychiatrists/diversity/education/transgender-and-gender-nonconforming-patients/gender-dysphoria-diagnosis.

Lavorato

Rampino

Giorgelli

. Gender dysphoria: overview and psychological interventions. In: Bettocchi

Busetto

Carrieri

Cormio

, eds. Practical Clinical Andrology. Cham: Springer; 2023:263-272. doi:10.1007/978-3-031-11701-5_20.

Nguyen

Chavez

Lipner

, et al. Gender-affirming hormone use in transgender individuals: impact on behavioral health and cognition. Curr Psychiatry Rep. 2018;20(12):110. doi:10.1007/s11920-018-0973-0.

Unger

CA.

Hormone therapy for transgender patients. Transl Androl Urol. 2016;5(6):877-884. doi:10.21037/tau.2016.09.04.

Zucker

Prendergast

BJ.

Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. doi:10.1186/s13293-020-00308-5.

Brabete

Greaves

Maximos

Huber

Lê

ML.

A sex- and gender-based analysis of adverse drug reactions: a scoping review of pharmacovigilance databases. Pharmaceuticals. 2022;15(3):298. doi:10.3390/ph15030298.

10.

Valeiro

Matos

Scholl

van Hunsel

Drug-induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database. Drug Saf. 2022;45(6):639-650. doi:10.1007/s40264-022-01174-3.

11.

Masumori

Nakatsuka

Cardiovascular risk in transgender people with gender-affirming hormone treatment. Circ Rep. 2023;5(4):105-113. doi:10.1253/circrep.CR-23-0021.

12.

Defreyne

Van de Bruaene

LDL

Rietzschel

Van Schuylenbergh

T’Sjoen

GGR

. Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons. Clin Chem. 2019;65(1):119-134. doi:10.1373/clinchem.2018.288241.

13.

Weinand

Safer

JD.

Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol. 2015;2(2):55-60. doi:10.1016/j.jcte.2015.02.003.

14.

Chan Swe

Ahmed

Eid

Poretsky

Gianos

Cusano

. The effects of gender-affirming hormone therapy on cardiovascular and skeletal health: a literature review. Metabol Open. 2022;13:Article 100173. doi:10.1016/j.metop.2022.100173.

15.

Yelehe

Klein

El Aridi

Maurier

Gillet

Feigerlova

Adverse effects of gender-affirming hormonal therapy in transgender persons: assessing reports in the French pharmacovigilance database. Fundam Clin Pharmacol. 2022;36(6):1115-1124. doi:10.1111/fcp.12806.

16.

FDA Adverse Events Reporting System (FAERS). Accessed February 1, 2021. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files.

17.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). MedDRA^® the Medical dictionary for regulatory activities. Accessed May 2023. https://www.meddra.org/.

18.

Hashemi

Weinreb

Weimer

Weiss

RL.

Transgender care in the primary care setting: a review of guidelines and literature. Fed Pract. 2018;35(7):30-37.

19.

Vin

Tangpricha

Joshua

Safer Transgender men: evaluation management. 2023. Accessed July 2, 2023. https://www.uptodate.com/contents/transgender-men-evaluation-and-management.

20.

Tangpricha

Safer

. Transgender women: evaluation and management. 2021. Accessed April 12, 2023. https://www.uptodate.com/contents/transgender-women-evaluation-and-management.

21.

FDA Label. Testosterone cypionate injection. Accessed May 15, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216318s000lbl.pdf.

22.

FDA label Depo®-Estradiol. Accessed May 15, 2023: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/085470s015lbl.pdf.

23.

Bhasin

Brito

Cunningham

, et al. Testosterone therapy in men with hypogonadism: an endocrine society: clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229.

24.

Michaud

Billups

Partin

AW.

Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015;7(6):378-387. doi:10.1177/1756287215597633.

25.

Araujo

Dixon

Suarez

Murad

Guey

Wittert

GA.

Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007-3019. doi:10.1210/jc.2011-1137.

26.

FDA Label. Aldactone^®. Accessed June 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf.

27.

Yang

Reckelhoff

JF.

Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hyper. 2011;20(2):133-138. doi:10.1097/MNH.0b013e3283431921.

28.

Mei

Williams

Webb

Shea

MacDonald

Al-Khazraji

BK.

Roles of hormone replacement therapy and menopause on osteoarthritis and cardiovascular disease outcomes: a narrative review. Front Rehabil Sci. 2022;3:825147. doi:10.3389/fresc.2022.825147.

29.

Chaudhary

Bashline

Novelli

, et al. Sex-related differences in clinical outcomes among patients with myocardial infarction with nonobstructive coronary artery disease: a systematic review and meta-analysis. International Journal of Cardiology. 2022;369:1-4. doi:10.1016/j.ijcard.2022.07.050.

30.

Strömberg

Mårtensson

Gender differences in patients with heart failure. Eur J Cardiovasc Nurs. 2003;2(1):7-18. doi:10.1016/S1474-5151(03)00002-1.

31.

Tamargo

Rosano

Walther

, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J: Cardiovasc Pharmacother. 2017;3(3):163-182. doi:10.1093/ehjcvp/pvw042.

32.

Mohseni-Alsalhi

Vesseur

MAM

Wilmes

, et al. The representation of females in studies on antihypertensive medication over the years: a scoping review. Biomedicines. 2023;11(5):1435. doi:10.3390/biomedicines11051435.

33.

Rivera

Tang

VAS

De Luna

, et al. Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: a systematic review and meta-analysis. Am Heart J Plus. 2023;26(2):100261. doi:10.1016/j.ahjo.2023.100261.

34.

Wiepjes

Nota

de Blok

CJM

, et al. The Amsterdam cohort of gender dysphoria study (1972–2015): trends in prevalence, treatment, and regrets. J Sex Med. 2018;15(4):582-590. doi:10.1016/j.jsxm.2018.01.016.

35.

Johannesson

Richards

Reddy

, et al. The first 5 years of uterus transplant in the US: a report from the United States Uterus Transplant Consortium. JAMA Surg. 2022;157(9):790. doi:10.1001/jamasurg.2022.2612.

36.

Hana

Butler

Young

Zamora

Lam

JSH

. Transgender health in medical education. Bull World Health Organ. 2021;99(4):296-303. doi:10.2471/BLT.19.249086.

37.

Palleria

Leporini

Chimirri

, et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two “challenging” case reports. J Pharmacol Pharmacother. 2013;4(Suppl 1):S66-S72. doi:10.4103/0976-500X.120955.

38.

Huang

Guo

Zalkikar

Tiwari

RC.

A review of statistical methods for safety surveillance. Ther Innov Regul Sci. 2014;48(1):98-108. doi:10.1177/2168479013514236.